Create Email Alert

Anthera Pharmaceuticals is based out of Hayward. Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.Whalewisdom has at least 2 13G filings, and 131 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2018-01-11. The notice included securities offered of Equity,Option, Warrant or Other Right to Acquire Another Security

Contact Info

anthera pharmaceuticals inc
HAYWARD CA    94545

Business Phone: (510) 856-5600

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year


Form D Filings

Form D is a form used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2018-01-11 D/A BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 15,000,000 15,000,000 0
2017-11-09 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 2,883,421 2,883,421 0
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
MAY LIU subscription required

Elevate your investments